2014
DOI: 10.1007/s40276-014-0022-x
|View full text |Cite|
|
Sign up to set email alerts
|

Analisi di costo efficacia dei nuovi anticoagulanti orali nella prevenzione dell’ictus in pazienti con fibrillazione atriale non valvolare in Italia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0
1

Year Published

2016
2016
2021
2021

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 30 publications
0
1
0
1
Order By: Relevance
“…These events were subsequently quantified using the costs reported in a recent Italian analysis, which assessed the cost-effectiveness of the non-vitamin k oral anticoagulants in the prevention therapy in NVAF patients [16]. An average cost of € 14,500 for the intracranial hemorrhage event (this amount takes into account the management of a moderate stroke -Barthel Index ≤ 14 and ≥ 10 -and a possible disability) and € 6,940.80 for the major extracranial bleeding event were considered.…”
Section: Number and Cost Of The Eventsmentioning
confidence: 99%
“…These events were subsequently quantified using the costs reported in a recent Italian analysis, which assessed the cost-effectiveness of the non-vitamin k oral anticoagulants in the prevention therapy in NVAF patients [16]. An average cost of € 14,500 for the intracranial hemorrhage event (this amount takes into account the management of a moderate stroke -Barthel Index ≤ 14 and ≥ 10 -and a possible disability) and € 6,940.80 for the major extracranial bleeding event were considered.…”
Section: Number and Cost Of The Eventsmentioning
confidence: 99%
“…Purtroppo, almeno fino a ora, tali provvedimenti non hanno ottenuto i risultati attesi, presentando ancora un rapporto rischio/beneficio sfavorevole. Queste considerazioni portano a ritenere che, nonostante la spesa per l'acquisto degli AVK sia irrisoria, la quota di budget sanitario pubblico impiegata risulti rilevante (2,53% vs 2% riportato dalla letteratura) (36). Pertanto, è auspicabile un miglioramento tecnico nella gestione degli AVK o l'impiego di una nuova classe di farmaci, quali i NAO, dotati di un profilo di sicurezza maggiore.…”
Section: Conclusioniunclassified